|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Predictive value of long-term changes of growth differentiation factor-15 over a 27-year-period for heart failure and death due to coronary heart disease.
|
29771963 |
2018 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Potential relation between soluble growth differentiation factor-15 and testosterone deficiency in male patients with coronary artery disease.
|
30819257 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma levels of novel biomarkers were significantly elevated (sST2, GDF-15, H-FABP, suPAR) or inversely downregulated (fetuin A) in patients with AMI compared to a control group with excluded coronary artery disease.
|
28683166 |
2017 |
|
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease.
|
28245821 |
2017 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease.
|
20855664 |
2010 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We tested if two of those markers, endothelin-1 (ET-1) and growth differentiation factor 15 (GDF-15), can be used as immunohistochemical markers for myocardial ischaemia/infarctions.
|
29151120 |
2018 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conducted a Mendelian randomisation study to examine the role of GDF-15 in risk of coronary artery disease (CAD) and breast and colorectal cancer.
|
31161347 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association of circulating growth differentiation factor-15, Krüppel-like factor 4 and growth arrest-specific 6 with coronary artery disease.
|
31153870 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.
|
27811204 |
2017 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Potential associations of circulating growth differentiation factor-15 with sex hormones in male patients with coronary artery disease.
|
30909145 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Growth Differentiation Factor 15 May Predict Mortality of Peripheral and Coronary Artery Diseases and Correlate with Their Risk Factors.
|
28798540 |
2017 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Study of the association between growth differentiation factor 15 gene polymorphism and coronary artery disease in a Chinese population.
|
21312063 |
2011 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because myocardial NRG-1/ErbB signaling has been documented to be impaired during HF associated with type 1 DM, we examined whether enhancement of NRG-1β signaling via exogenous administration of recombinant NRG-1β could exert beneficial effects against post-MI HF in the type 1 diabetic heart.
|
28870731 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma GDF-15 is an independent predictor of all-cause mortality in Chinese patients with HF.
|
28612904 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The hazard ratio for the composite end point for the highest compared to the lowest quartile of GDF-15 was 1.8 (95% CI, 1.5-2.2); for CV death, 2.63 (1.9-3.6); for sudden death, 3.06 (1.9-4.8); for heart failure (HF) death, 4.3 (1.3-14); for cancer death, 2.5 (1.3-4.7); for hospitalization for HF, 5.8 (3.2-10); for MI 1.4 (95% CI, 1.1-1.9); and for stroke, 1.8 (95% CI, 1.1-2.8).
|
27811204 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Discrimination of subjects with and without HF was slightly higher for GDF-15 (area under the ROC curve [AUC]:0.79 [95%CI:0.75-0.83]) compared to NT-proBNP (AUC:0.77 [95% CI:0.72-0.82]).
|
27838133 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 is induced in hypertrophic and dilated cardiomyopathy after volume overload, ischemia, and heart failure.
|
31663791 |
2020 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
NRG-1/ErbB2 gene polymorphisms were not associated with heart failure risk or prognosis.
|
26844763 |
2016 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although, in general, effects of NRG-1 in heart failure are compensatory and beneficial, translation into therapies remains unaccomplished both because of the complexity of the underlying pathways and because of the challenges in the development of therapeutics (proteins, peptides, small molecules, and RNA-based therapies) for tyrosine kinase receptors.
|
31607147 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition to regulating body weight, MIC-1/GDF15 may be used to predict mortality and/or disease course in cancer, cardiovascular disease (CVD), chronic renal and heart failure, as well as pulmonary embolism.
|
20854422 |
2010 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Growth/differentiation factor 15 (GDF15), also known as MIC-1, is a distant member of the transforming growth factor-β (TGF-β) superfamily and has been implicated in various biological functions, including cancer cachexia, renal and heart failure, atherosclerosis and metabolism.
|
28846098 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, seven groups of biomarkers associated to myocardial stretch (mid-regional proatrial natriuretic peptide, MR-proANP), myocyte injury (high-sensitive troponins, hs-cTn; heart-type fatty acid-binding protein, H-FABP; glutathione transferase P1, GSTP1), matrix remodeling (galectin-3; soluble isoform of suppression of tumorigenicity 2, sST2), inflammation (growth differentiation factor-15, GDF-15), renal dysfunction (neutrophil gelatinase-associated lipocalin, NGAL; kidney injury molecule-1, KIM-1), neurohumoral activation (adrenomedullin, MR-proADM; copeptin), and oxidative stress (ceruloplasmin; myeloperoxidase, MPO; 8-hydroxy-2'-deoxyguanosine, 8-OHdG; thioredoxin 1, Trx1) in HF will be overviewed.
|
28212715 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In pooled analysis of both cohorts, higher levels of nine proteins were associated with incident heart failure after adjustment for established risk factors: growth differentiation factor 15 (GDF-15), T-cell immunoglobulin and mucin domain 1 (TIM-1), tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), spondin-1 (SPON1), matrix metalloproteinase-12 (MMP-12), follistatin (FS), urokinase-type plasminogen activator surface receptor (U-PAR), osteoprotegerin (OPG), and suppression of tumorigenicity 2 (ST2).
|
28967680 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the setting of ACS, GDF-15 is associated with long-term all-cause death, MACE and heart failure and provides incremental prognostic value beyond traditional risks factor.
|
31369736 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
|
31423712 |
2019 |